Health Care • Biotechnology: Pharmaceutical Preparations
$4.79 ▼ -0.38
(-7.35%)
MKT CAP: $145.9M • VOL: 142.6K
52W L $4 52W H $10
DERM // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $61.2M | $55.1M | $59.7M |
| YoY Revenue Growth % | +11.1% | -7.6% | — |
| Gross Profit | $40.3M | $34.3M | — |
| Gross Margin % | 65.8% | 62.1% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$8.2M | -$13.7M | -$2.1M |
| Operating Margin % | -13.3% | -24.8% | -3.5% |
| Net Income (GAAP) | -$11.4M | -$14.7M | -$3.9M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$12.4M | -$9.1M | $5.2M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | -$12.4M | -$9.1M | $5.2M |
| FCF Margin % | -20.3% | -16.6% | 8.8% |
| Return on Invested Capital (ROIC %) | -19.5% | -43.8% | — |
| Cash & Short-Term Equivalents | $24.1M | $20.3M | — |
| Total Debt (Short + Long Term) | $25.3M | $24.9M | — |
| Total Stockholders' Equity | $31.9M | $20.1M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR DERM.